APA (7th ed.) Citation

D, B., KJM, v. d. V., A, B., HP, v. d. B., AM, B., MJ, v. d. D., . . . IM, v. O. (2026). From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer. Drugs - real world outcomes, 13(2), 183. https://doi.org/10.1007/s40801-026-00548-8

Chicago Style (17th ed.) Citation

D, Bosch, et al. "From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer." Drugs - Real World Outcomes 13, no. 2 (2026): 183. https://doi.org/10.1007/s40801-026-00548-8.

MLA (9th ed.) Citation

D, Bosch, et al. "From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer." Drugs - Real World Outcomes, vol. 13, no. 2, 2026, p. 183, https://doi.org/10.1007/s40801-026-00548-8.